Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
about
Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug ReactionExposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype.Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumorAssessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine.Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 ProteinsStructure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles.Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.Renal Drug Transporters and Drug Interactions.Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells.Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response.Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates.Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach.Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma.Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma.Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma.
P2860
Q28550377-A8089231-5736-4B3F-9176-F1A6004E7234Q33411001-A0261BBA-D803-4740-89AF-60BA7DDEA5DAQ33418378-B671AB80-76AB-4159-A13B-5181B9405E7DQ33419367-F11B25A1-E973-410D-A6A5-2CCF6EFF8FE1Q33425872-B44AD7AF-1020-4473-814F-C80A6400BE68Q33437427-C60079FF-54DD-47CA-A6BE-3336CD71916EQ34871636-711B5F7C-0DE4-417B-9F80-F197517A1D40Q35639659-103931F5-A553-4B5D-A58E-D844E2A8EF9CQ35795744-B1974E27-4546-4BFF-BB99-E5297BD4349EQ38207943-890C2493-B9B3-4767-A504-72BE44BC2EE4Q38379295-D42CE4E2-4D50-4552-9525-9DEAC30F5E54Q38414396-6308DFEA-3182-4ABE-9EFC-24510C2A6B62Q38720430-F2A941B1-92AA-4175-BE66-60F1B603C719Q39140289-0CF56DE4-5B0E-489B-BB96-FBC60473637CQ41921173-F6869E2B-2998-433E-A4B1-7243BD9F5F95Q46109720-2B6DED35-33CE-4E05-B2A0-8152B6ADFA42Q47847397-148ECBC0-E763-4255-ACC2-BA3F80AAFF9AQ47957959-EBBA0A49-595B-4D1E-BE23-278AD3649E82Q48306032-E61406BB-C394-4AD2-AB7C-BE9D72835F20Q48811919-3C220296-4244-472A-BB9D-FADC5984368CQ50927629-BB515DD6-3B65-4961-81C2-315EBC7C2F4DQ51537517-AA9C85B1-D3EE-4330-AA24-FA702278574BQ52571238-2BB7BB74-95E8-4BB3-979F-BA5F82886DD7Q55031642-37442396-449F-427B-8762-54C9A32A8520
P2860
Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Impact of genetic variation in ...... on sunitinib pharmacokinetics.
@ast
Impact of genetic variation in ...... on sunitinib pharmacokinetics.
@en
type
label
Impact of genetic variation in ...... on sunitinib pharmacokinetics.
@ast
Impact of genetic variation in ...... on sunitinib pharmacokinetics.
@en
prefLabel
Impact of genetic variation in ...... on sunitinib pharmacokinetics.
@ast
Impact of genetic variation in ...... on sunitinib pharmacokinetics.
@en
P2093
P1476
Impact of genetic variation in ...... on sunitinib pharmacokinetics.
@en
P2093
Eijiro Nakamura
Ken-Ichi Inui
Masahide Fukudo
Osamu Ogawa
Tomohiro Terada
Tomomi Kamba
Tomoyuki Mizuno
Toshiya Katsura
P304
P356
10.2133/DMPK.DMPK-12-RG-026
P577
2012-06-05T00:00:00Z